Test Code ADMI ADAMTS13 Interpretation
Specimen Required
Only orderable as part of a profile. For more information see ADAMP / ADAMTS13 Activity with Reflex Inhibitor Profile, Plasma.
Useful For
Technical interpretation of testing performed to assist in the diagnosis of congenital, immune, or acquired thrombotic thrombocytopenic purpura
Method Name
Only orderable as part of profile. For more information see ADAMP / ADAMTS13 Activity with Reflex Inhibitor Profile, Plasma
Technical Interpretation
Reporting Name
ADAMTS13 InterpretationSpecimen Type
Plasma Na CitSpecimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Plasma Na Cit | Frozen |
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.Clinical Information
Thrombotic thrombocytopenic purpura (TTP), a rare (estimated incidence of 3.7 cases per million) and potentially fatal thrombotic microangiopathy syndrome, is characterized by a pentad of symptoms: thrombocytopenia, microangiopathic hemolytic anemia (intravascular hemolysis and presence of peripheral blood schistocytes), neurological symptoms, fever, and kidney dysfunction. A large majority of patients initially present with thrombocytopenia and peripheral blood evidence of microangiopathy and, in the absence of any other potential explanation for such findings, satisfy criteria for early initiation of plasma exchange, which is critical for patient survival. TTP may rarely be congenital (Upshaw-Shulman syndrome) but, far more commonly, is acquired. Acquired TTP may be considered primary or idiopathic (the most frequent type) or associated with distinctive clinical conditions (secondary TTP) such as medications, hematopoietic stem cell or solid organ transplantation, sepsis, and malignancy.
The isolation and characterization of an IgG autoantibody frequently found in patients with idiopathic TTP clarified the basis of this entity and led to the isolation and characterization of a metalloprotease called ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 motif 13 repeats), which is the target for the IgG autoantibody, leading to a functional deficiency of ADAMTS13. ADAMTS13 cleaves the ultra-high-molecular-weight multimers of von Willebrand factor (VWF) at the peptide bond Tyr1605-Met1606 to disrupt VWF-induced platelet aggregation. The IgG antibody prevents this cleavage and leads to TTP. Although the diagnosis of TTP may be confirmed with ADAMTS13 activity and inhibition studies, the decision to initiate plasma exchange should not be delayed pending results of this assay.
ADAMTS13 activity results can have an impact on overall survival, ultimate clinical outcome, responsiveness to plasma exchange, and relapse are still controversial in recent literature. Therefore, clinical correlation is essential.
Reference Values
Only orderable as part of profile. For more information see ADAMP / ADAMTS13 Activity with Reflex Inhibitor Profile, Plasma.
ADAMTS13 ACTIVITY ASSAY
≥70%
ADMTS13 INHIBITOR TITER
<0.5 BU
Interpretation
Interpretive comments are provided.
Less than 10% ADAMTS13 activity is highly indicative of thrombotic thrombocytopenic purpura (TTP) in an appropriate clinical setting.
Day(s) Performed
Monday through Sunday
Report Available
3 to 5 daysSpecimen Retention Time
7 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
Not ApplicableLOINC Code Information
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
621149 | ADAMTS13 Interpretation | 69049-5 |
621150 | ADAMTS13 Interpretation | No LOINC Needed |